证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-054 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 （1）保证期间根据主合同项下债权人对债务人所提供的每笔融资分别计算，就每笔融资而言，保证期 间为该笔融资项下债务履行期限届满之日起三年。 重要内容提示： ● 担保对象及基本情况 （一）担保的基本情况 2025年11月20日，青岛蔚蓝生物股份有限公司（以下简称"公司"）与兴业银行股份有限公司青岛分行签 署了《最高额保证合同》，为公司全资子公司青岛蔚蓝生物集团有限公司（以下简称"蔚蓝生物集团"） 在该行开展的授信业务提供连带责任保证担保，担保总额为人民币8,000.00万元。 （二）内部决策程序 上述担保事项已经公司2025年4月25日召开的第五届董事会第十六次会议审议通过，并经公司于2025年5 月16日召开的2024年年度股东会批准。具体内容详见公司分别于2025年4月26日、2025年5月17日在上海 证券交易所网站披露的《青岛蔚蓝生物股份有限公司关 ...

证券日报网讯 11月21日晚间，蔚蓝生物发布公告称，2025年11月20日，公司与兴业银行股份有限公司 青岛分行签署了《最高额保证合同》，为公司全资子公司青岛蔚蓝生物集团有限公司在该行开展的授信 业务提供连带责任保证担保，担保总额为人民币8，000.00万元。 （文章来源：证券日报） ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-054 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 青岛蔚蓝生物集团有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 8,000.00 | 万元 | | | 担保对象 | 实际为其提供的担保余额 | 26,355.49 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股 | 123,020.00 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 70.79 ...

Core Viewpoint - The company has signed a guarantee contract with Industrial Bank Qingdao Branch to provide a joint liability guarantee for its wholly-owned subsidiary's credit business of 80 million yuan, which has been approved by the board and shareholders [1] Financial Summary - As of the announcement date, the company's actual guarantee balance is 263.55 million yuan, and the total external guarantees provided by the company and its subsidiaries amount to 1.23 billion yuan, representing 70.79% of the audited net assets as of the end of 2024, with no overdue guarantees [1] - For the period from January to September 2025, the revenue of the company is 728.50 million yuan, and the net profit is 117.32 million yuan [1]

Core Points - The company held its first extraordinary general meeting of shareholders on November 13, 2025, where no resolutions were rejected [2] - The meeting was chaired by the financial director due to the absence of the chairman and general manager [3] - The company approved the proposal to abolish the supervisory board and amend the articles of association, transferring the supervisory powers to the audit committee of the board [9] Meeting Details - The meeting took place at the company's innovation park in Qingdao [2] - The voting method combined on-site and online voting, complying with the Company Law and the company's articles of association [2] - Out of 5 current directors, 3 attended the meeting, while 1 supervisor attended out of 3 [3] Resolutions Passed - The following proposals were approved: - Abolishment of the supervisory board and amendment of the articles of association [4] - Amendments to various governance documents, including the rules for shareholder meetings, board meetings, independent director systems, and management of fundraising [4][5][6] - The proposals requiring special resolutions received over two-thirds of the votes from participating shareholders [6] Legal Confirmation - The meeting was witnessed by Beijing Hairun Tianrui Law Firm, confirming that the meeting's procedures complied with legal requirements [6]

Core Viewpoint - The company announced the election of Mr. Li Yuqiang as the employee representative director for the fifth board of directors during the employee representative meeting scheduled for November 13, 2025 [2] Group 1 - The employee representative meeting is set to take place on November 13, 2025 [2] - Mr. Li Yuqiang has been nominated for the position of employee representative director [2]

青岛蔚蓝生物股份有限公司 青岛蔚蓝生物股份有限公司董事会 关于选举第五届董事会职工代表董事的公告 2025 年 11 月 14 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 简历： 青岛蔚蓝生物股份有限公司（以下简称"公司"）于 2025 年 11 月 13 日召开 2025 年第一次临时股东会，审议通过了《关于取消监事会并修订<公司章程>的 议案》。本次修订后，公司不再设置监事会，其职权由董事会审计委员会行使， 同时在董事会中设立职工代表董事席位。 公司于同日召开职工代表大会，经与会职工代表审议，同意选举李玉强先生 为公司第五届董事会职工代表董事（简历见附件）。李玉强先生将与公司第五届 董事会非职工代表董事共同组成第五届董事会，任期自公司本次职工代表大会审 议通过之日起至第五届董事会届满之日止。 李玉强先生符合《公司法》等法律法规关于董事的任职资格和条件，并将按 照相关法律法规的规定行使职权。本次选举完成后，公司董事会中兼任公司高级 管理人员以及由职工代表担任的董事人数总计不超过公司董事总数的二分之一。 证券代码：60 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-052 青岛蔚蓝生物股份有限公司 2025年第一次临时股东会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 102 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 166,723,780 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 65.8912 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式召开。 公司董事长兼总经理陈刚因出差在外无法出席本次股东会，经过半数董事推选， (一) 股东会召开的时间：2025 年 11 月 13 日 (二) 股东会召开的地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会议室 (三) 出席会议的普通股股东和恢 ...

北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 2025 年第一次临时股东会的 法律意见书 中国·北京 地址：朝阳区建外大街甲 14 号广播大厦 5 层、9 层、10 层、13 层、17 层 邮编：100022 电话：（010）65219696 传真：（010）88381869 二〇二五年十一月 北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 2025 年第一次临时股东会的法律意见书 致：青岛蔚蓝生物股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受青岛蔚蓝生物股份有限 公司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第一次临时股 东会，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治 理准则》《公司章程》及其他相关法律、法规的规定，就公司本次股东会的召集、 召开程序、出席会议人员的资格、召集人资格、表决程序及表决结果等有关事宜 出具本法律意见书。 对本法律意见，本所律师声明如下： 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行 ...

Group 1: Report General Information - The report is about a research on Weilan Biology in the agricultural, livestock, and fishery industry on November 5, 2025 [1][2][17] Group 2: Research Participants - The research was participated by investors through online questions [2] - The company's reception staff included the chairman and general manager Chen Gang, director and financial controller Qiao Piyuan, board secretary Jiang Yong, and independent directors Lin Yingtin and Wang Jing [17] Group 3: Company's Development Strategy - The company focuses on the biological industry, aiming to become a world - class high - tech biological enterprise. It will form a new development pattern of "one body with two wings", building an industrial biological platform company driven by technological innovation and globalization [24] - The company adheres to technological innovation as the core strategy and has launched the "ecological innovation" strategy, building an open - innovation ecosystem [24] - The company takes global layout as an important strategy, aiming to increase the proportion of overseas revenue and expand into key regions like Southeast Asia and Africa [25][26] Group 4: Q3 Financial Performance - In Q3 2025, the company's operating income was 363.5997 million yuan, a year - on - year increase of 8.09% due to product sales structure adjustment; the net profit attributable to the parent was 35.0628 million yuan, a year - on - year increase of 205.02% due to the recognition of income from cooperation partners [26] Group 5: Technical Advantages in Animal Health - The company builds an "industry + service" comprehensive empowerment platform in the animal health field, providing systematic solutions [27] - The VLAND - PCP customized enzyme program has a database covering over a hundred feed ingredients, improving feed conversion efficiency and livestock growth performance [27] Group 6: R & D Investment and Progress - In the first three quarters of 2025, the company's R & D investment was 100.2386 million yuan, accounting for 9.87% of operating income, a year - on - year increase of 23.29% [28] - The company has 6 technology centers and 2 key laboratories, adopting a "dual - leadership" management model and an IPD system for R & D management [29][30] - The company cooperates with over 20 universities and research institutes and 60 large - and medium - sized production enterprises for R & D [30] Group 7: Microbial Technology in Environmental Protection - The company established the Weilan Saide Environmental Microbial Laboratory, applying microbial technology to environmental protection, but the business revenue accounts for a relatively small proportion [31]